Philip Morris Products SA Invalidates Patent in Court Victory

Jul.03.2022
Philip Morris Products successfully invalidated a patent claim over e-cigarette design by Renovo Tobacco, following litigation.

Philip Morris Products SA, a subsidiary of Philip Morris International Inc., has succeeded in convincing an administrative court that one of Reynolds Tobacco's patents covering the design of vapor electronic cigarettes is partially invalid. In 2020, Reynolds Tobacco and RJ Reynolds Vapor Co. filed a patent infringement lawsuit against Philip Morris International, claiming six patents, including the invalidated patent at issue.

 

On Thursday, the Patent Trial and Appeal Board stated that two claims in the U.S. Patent No. 9,814,268 are invalid. The patent pertains to an electronic smoking device containing tobacco that is designed to burn a small amount.

 

This article contains excerpts or reproductions from third-party sources, with the copyright belonging to the original media and authors. If there is any infringement, please contact us for removal. Any organization or individual who wishes to reprint should contact the author and not do so directly.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
Shenzhen e-commerce companies dominate 2025 Top 500 list, including 13 e-cigarette businesses. Shenzhen FirstUnion Tech climbs 57 spots.
Oct.30 by 2FIRSTS.ai
BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Rothmans introduces "glo hyper" series promotion in South Korea, with "glo hyper pro" for $20 and "glo hyper" for $14.
Oct.15 by 2FIRSTS.ai
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Inc. (JT) has announced a series of executive and board appointments effective from 2026, including the nomination of Takehiko Tsutsui—currently Executive Vice President at JT International—as President, CEO and Representative Director.
Nov.26
Smoking Rate Drops to 17.9%, Vaping Rate Climbs to 9.3% in South Korea
Smoking Rate Drops to 17.9%, Vaping Rate Climbs to 9.3% in South Korea
The Korea Disease Control and Prevention Agency (KDCA) released its 2025 Community Health Survey results covering more than 230,000 adults. Traditional cigarette smoking dropped to 17.9%, down 1 percentage point from last year, while e-cigarette use increased to 9.3%, up 0.6 points. Overall tobacco product use stood at 22.1%, a slight decline from 2024 but still 0.5 points higher than 2019.
Dec.08 by 2FIRSTS.ai
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA has reached a settlement with Washington State and agreed to pay $66 million to resolve disputes over annual payments under the 1998 Master Settlement Agreement (MSA) for the period 2005–2015.
Nov.04 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21